$RVPH
REVIVA PHARMACEUTICALS HOLDINGS, INC.

2023 Q4 Form 10-Q Financial Statement

#000143774923031973 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.512M $1.992M
YoY Change 2.42% 58.46%
% of Gross Profit
Research & Development $8.476M $8.717M
YoY Change 34.6% 278.03%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $9.988M $10.71M
YoY Change 28.49% 200.57%
Operating Profit -$10.71M
YoY Change 200.57%
Interest Expense $192.7K $5.901K
YoY Change 53.16% -88.08%
% of Operating Profit
Other Income/Expense, Net $66.76K $230.1K
YoY Change -114.46% 364.83%
Pretax Income -$9.729M -$10.48M
YoY Change 19.96% 198.25%
Income Tax -$4.580K $12.12K
% Of Pretax Income
Net Earnings -$9.724M -$10.50M
YoY Change 19.78% 200.0%
Net Earnings / Revenue
Basic Earnings Per Share -$0.44
Diluted Earnings Per Share -$0.36 -$0.44
COMMON SHARES
Basic Shares Outstanding 22.65M 22.65M
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $23.37M $4.972M
YoY Change 26.18% -78.56%
Cash & Equivalents $23.37M $4.972M
Short-Term Investments
Other Short-Term Assets $332.9K $414.7K
YoY Change -17.55% -51.15%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $23.70M $5.387M
YoY Change 25.24% -77.59%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $1.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $23.70M $5.387M
Total Long-Term Assets $0.00 $1.00
Total Assets $23.70M $5.387M
YoY Change 25.24% -77.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.849M $5.278M
YoY Change 9.34% 124.82%
Accrued Expenses $13.33M $7.532M
YoY Change 428.9% 513.41%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $222.5K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $17.18M $13.03M
YoY Change 184.36% 264.49%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $806.7K $873.4K
YoY Change 42.16% 726.31%
Total Long-Term Liabilities $806.7K $873.4K
YoY Change 42.16% 726.31%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.18M $13.03M
Total Long-Term Liabilities $806.7K $873.4K
Total Liabilities $17.98M $13.91M
YoY Change 172.15% 277.75%
SHAREHOLDERS EQUITY
Retained Earnings -$134.4M -$120.7M
YoY Change 47.37% 45.25%
Common Stock $2.792K $2.265K
YoY Change 36.53% 10.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.719M -$8.519M
YoY Change
Total Liabilities & Shareholders Equity $23.70M $5.387M
YoY Change 25.24% -77.59%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$9.724M -$10.50M
YoY Change 19.78% 200.0%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$8.876M -$6.178M
YoY Change 89.24% 54.37%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 27.27M 350.0
YoY Change 146837.5% -100.0%
NET CHANGE
Cash From Operating Activities -8.876M -6.178M
Cash From Investing Activities
Cash From Financing Activities 27.27M 350.0
Net Change In Cash 18.40M -6.178M
YoY Change -493.73% -263.78%
FREE CASH FLOW
Cash From Operating Activities -$8.876M -$6.178M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.87
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19269989
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22775407
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18737330
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1621187 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
350410 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4972298 usd
CY2023Q3 us-gaap Assets
Assets
5387041 usd
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20650266
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8717273 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1991774 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1256972 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10709047 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3562953 usd
rvph Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
403 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6571629 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
10709047 usd
us-gaap Net Income Loss
NetIncomeLoss
-29536434 usd
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
22650266
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1303000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20447371
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
103485612 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-91171261 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
12316396 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18923675 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2305981 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22943522 usd
CY2022Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
0 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3520271 usd
CY2022Q4 rvph Accrued Liabilities And Other Current Liabilities
AccruedLiabilitiesAndOtherCurrentLiabilities
2519569 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6039840 usd
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
567439 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
112185998 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-120707695 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-8519432 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5387041 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12650388 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3882210 usd
us-gaap Operating Expenses
OperatingExpenses
29515151 usd
us-gaap Operating Expenses
OperatingExpenses
16532598 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-29515151 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-16532598 usd
CY2023Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
139079 usd
CY2022Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
0 usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-305972 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
5901 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
-0 usd
us-gaap Interest Expense
InterestExpense
20414 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
91763 usd
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
53150 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
341854 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5194 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3641 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15220 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3513444 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29514903 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12117 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1864 usd
us-gaap Net Income Loss
NetIncomeLoss
-29536434 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.30
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24033665
us-gaap Net Income Loss
NetIncomeLoss
-16221020 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001742927
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
414743 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
403819 usd
CY2022Q4 us-gaap Assets
Assets
18923675 usd
CY2023Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
222500 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5278375 usd
CY2023Q3 rvph Accrued Liabilities And Other Current Liabilities
AccruedLiabilitiesAndOtherCurrentLiabilities
7532187 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
667500 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
13033062 usd
CY2023Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
873411 usd
CY2023Q3 us-gaap Liabilities
Liabilities
13906473 usd
CY2022Q4 us-gaap Liabilities
Liabilities
6607279 usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20650266
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20447371
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
2265 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2045 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
3562953 usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
267031 usd
us-gaap Interest Expense
InterestExpense
-0 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
68710 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
230135 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
323992 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16208606 usd
us-gaap Net Income Loss
NetIncomeLoss
-16221020 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10491029 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-8519432 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
12316396 usd
rvph Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
5677850 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3022756 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-8519432 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
16060380 usd
CY2022Q3 rvph Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
333 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7773527 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
40587 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3515308 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
20359519 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
28686460 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7773527 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
120149 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
20359519 usd
us-gaap Net Income Loss
NetIncomeLoss
-29536434 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
305972 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-267031 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3022756 usd
us-gaap Share Based Compensation
ShareBasedCompensation
120149 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
10924 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1074587 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1758104 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1630662 usd
rvph Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
5012618 usd
rvph Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-607294 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19447908 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14269947 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
0 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
445000 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
-0 usd
rvph Proceeds From Issuance Or Sale Of Equity Net
ProceedsFromIssuanceOrSaleOfEquityNet
0 usd
rvph Proceeds From Issuance Or Sale Of Equity Net
ProceedsFromIssuanceOrSaleOfEquityNet
7773527 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
5677850 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
403 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5900350 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7773930 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-13547558 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-6496017 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18519856 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
29687944 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4972298 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
23191927 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
18674 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
4981 usd
us-gaap Interest Paid Net
InterestPaidNet
20414 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023Q3 rvph Prepaid Expenses Included In Accounts Payable
PrepaidExpensesIncludedInAccountsPayable
0 usd
CY2022Q3 rvph Prepaid Expenses Included In Accounts Payable
PrepaidExpensesIncludedInAccountsPayable
207553 usd
CY2023Q3 rvph Working Capital
WorkingCapital
-7600000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-120700000 usd
CY2023Q3 us-gaap Cash
Cash
5000000.0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0343 pure
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10500000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3500000 usd
us-gaap Net Income Loss
NetIncomeLoss
-29500000 usd
us-gaap Net Income Loss
NetIncomeLoss
-16200000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><span style="text-decoration: underline; ">Use of estimates</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;text-indent:18pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. Significant areas requiring the use of management estimates include, but are not limited to, depreciation and amortization, useful lives, assumptions used to calculate the fair value of stock-based compensation, deferred taxes, and related valuation allowances. Actual results could differ materially from such estimates under different assumptions or circumstances.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><span style="text-decoration: underline; ">Concentration of credit risk and other risks and uncertainties</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. Currently, substantially all the Company’s cash and cash equivalents are held in demand deposit form at two financial institutions. Deposits in financial institutions may, from time to time, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">The Company is subject to all of the risks inherent in an early-stage company developing new pharmaceutical products. These risks include, but are not limited to, limited management resources, dependence upon medical acceptance of products in development, regulatory approvals, successful clinical trials, availability and willingness of patients to participate in human trials, and competition in the pharmaceutical industry. The Company’s operating results may be materially affected by the foregoing factors.</p>
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17717983
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18417231
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17717983
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18417231
CY2022Q3 us-gaap Share Price
SharePrice
2.20
CY2023Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.74
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
260000
CY2023Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.13
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
350410 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
40587 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3022756 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
120149 usd
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4204281 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
120000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
4.80
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.60
CY2023Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
222500 usd

Files In Submission

Name View Source Status
0001437749-23-031973-index-headers.html Edgar Link pending
0001437749-23-031973-index.html Edgar Link pending
0001437749-23-031973.txt Edgar Link pending
0001437749-23-031973-xbrl.zip Edgar Link pending
ex_593876.htm Edgar Link pending
ex_593877.htm Edgar Link pending
ex_593886.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rvph-20230930.xsd Edgar Link pending
rvph20230929_10q.htm Edgar Link pending
Show.js Edgar Link pending
rvph-20230930_cal.xml Edgar Link unprocessable
rvph-20230930_def.xml Edgar Link unprocessable
rvph-20230930_lab.xml Edgar Link unprocessable
rvph-20230930_pre.xml Edgar Link unprocessable
rvph20230929_10q_htm.xml Edgar Link completed